LivaNova

LIVN · NASDAQ

$80.90−$0.37 (−0.46%)TodayMarket closed · Oct 23, 7:30 PM ET

Prev close $81.27

LIVN analyst rating

BuyConsensus of 9 analysts over the last 12 months. 78% rate it a buy.

Strong buy0
Buy7
Hold2
Underperform0
Sell0

12-month price target · 12 analysts

Average $91.03 (+12.5% upside)

Low: $75.75
Now: $80.90
High: $105.00

Upgrades and downgrades

The latest rating actions, newest first

LIVN analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Barclays	Oct 7, 2026	Initiates	Overweight	$105.00	70%
Piper Sandler	Sep 2, 2026	Maintains	Overweight	$87.00 → $90.00	52%
Needham	Aug 5, 2026	Maintains	Buy	$81.00 → $93.00	46%
Mizuho	Jul 15, 2026	Maintains	Outperform	$90.00 → $95.00	56%
Freedom Capital Markets	Jul 1, 2026	Initiates	Hold	$81.00	50%
Keybanc	Jun 22, 2026	Maintains	Overweight	$83.00 → $92.00	56%
Barclays	May 7, 2026	Maintains	Equal-Weight	$73.00 → $76.00	57%
Mizuho	May 7, 2026	Maintains	Outperform	$85.00 → $90.00	56%
Baird	May 7, 2026	Maintains	Outperform	$78.00 → $76.00	67%
Barclays	Feb 27, 2026	Maintains	Equal-Weight	$67.00 → $73.00	57%

The case for and against

Updated Feb 9, 2026

Bull case

LivaNova's sales have experienced significant growth, with reported figures of $803 million in 2024, and management forecasts an increase to between $940 million and $955 million for the upcoming year. The company's strategic focus on cardiopulmonary solutions and neuromodulation devices positions it well within high-demand segments, indicating robust revenue potential. Additionally, projections for the aura6000 device suggest a potential increase in market share and sales, with estimates ranging from $120 million in 2027 to $280 million by 2029 under favorable conditions, contributing positively to LivaNova's growth outlook.

Bear case

LivaNova's financial outlook is negatively impacted by anticipated revenue growth slowing to the low-single digits, primarily due to ongoing challenges in its Neuromodulation and Cardiovascular segments. The company's operating margins are expected to contract, contributing to earnings falling below market consensus. Additional risks include the potential failure to secure FDA approval for the aura6000, coupled with slower than expected growth and weaker margin improvements in both its Neuromodulation and Cardiopulmonary divisions.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.